LLY - Eli Lilly and Company

NYSE - Nasdaq Real Time Price. Currency in USD
87.27
+0.77 (+0.89%)
As of 10:51AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close86.50
Open86.89
Bid87.39 x 100
Ask87.41 x 400
Day's Range86.62 - 87.61
52 Week Range71.76 - 89.09
Volume1,697,191
Avg. Volume3,307,771
Market Cap91.388B
Beta0.12
PE Ratio (TTM)41.54
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.25 (2.56%)
Ex-Dividend Date2017-11-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
    Zacks3 hours ago

    Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

    This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

  • Market Realistyesterday

    Bristol-Myers Squibb’s Valuation in December 2017

    Headquartered in New York City, pharmaceutical giant Bristol-Myers Squibb (BMY) offers various cardiovascular, immunoscience, neuroscience, oncology, and virology products.

  • Lilly Issues Guidance for 2018, New Drugs to Drive Top Line
    Zacksyesterday

    Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

    Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkeyyesterday

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Barrons.com2 days ago

    Eli Lilly: Updated Guidance Is a Shot in the Arm

    Shares of Eli Lilly (LLY) are climbing on Wednesday, after the drug maker's updated guidance for this year and next. Eli Lilly said that it expects to earn between $4.15 and $4.25 a share for fiscal 2017, on revenues of $22.4 billion to $22.7 billion. For fiscal 2018, Eli Lilly said it expects to earn between $4.60 and $4.70 a share, on revenue of $23 billion to $23.5 billion.

  • Reuters2 days ago

    Lilly's 2018 forecast beats on strength of new drugs

    Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz. Lilly said it was expecting a regulatory decision on its rheumatoid arthritis drug baricitinib, whose marketing application was initially rejected by the U.S. Food and Drug Administration. The drugmaker also expects to launch a new indication for Taltz in psoriatic arthritis.

  • CNBC2 days ago

    Stocks making the biggest moves premarket: HON, LLY, AMGN, TM, HD & more

    These are the stocks posting the largest moves before the bell.

  • Market Realist3 days ago

    What Analysts Recommend for Eli Lilly in December 2017

    In October 2017, Eli Lilly (LLY) and CureVac announced a global collaboration for immuneoncology research.

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks3 days ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Market Realist3 days ago

    How Is Olumiant Positioned after 3Q17?

    In 3Q17, Eli Lilly's (LLY) Olumiant (baricitinib) reported revenues of $16.2 million compared to $4.8 million and $1.9 million in 2Q17 and 1Q17, respectively.

  • Market Realist3 days ago

    How Eli Lilly’s Animal Health Products Performed in 3Q17

    In 3Q17, Eli Lilly’s (LLY) Animal Health segment reported revenues of $740.6 million, a ~5% increase on a year-over-year (or YoY) basis and a 6% decline on a quarter-over-quarter basis.

  • MarketWatch4 days ago

    Eli Lilly hikes dividend by 8%

    Eli Lilly and Co. said Monday its board approved an 8% hike in its quarterly dividend. The drugmaker said it will pay a 56.25 cents a share dividend in the first quarter to shareholders of record as of ...

  • Lilly Reports Mixed Results from Late-Stage Cyramza Study
    Zacks4 days ago

    Lilly Reports Mixed Results from Late-Stage Cyramza Study

    Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.

  • Reuters4 days ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters4 days ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • Market Realist4 days ago

    An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar

    In 3Q17, Eli Lilly's (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.

  • Market Realist4 days ago

    How Is Eli Lilly’s Neuroscience Portfolio Positioned after 3Q17?

    In 3Q17, Zyprexa generated revenues of $140.6 million, a ~6% decline on a YoY basis.

  • Market Realist4 days ago

    How Has Eli Lilly’s Cyramza Performed

    In 3Q17, Eli Lilly's (LLY) Cyramza generated revenues of $196 million, which reflected ~23% growth on a YoY basis and 5% growth on a quarter-over-quarter basis.

  • Reuters7 days ago

    Lilly's stomach cancer drug meets main goal, but fails to improve survival rate

    Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates. The company said it would not seek a regulatory approval based on the results. The study tested Cyramza in combination with other drugs as a first-line treatment for patients with advanced forms of gastric cancer, which is estimated to result in the deaths of nearly 11,000 people in the United States this year.

  • Reuters7 days ago

    Lilly's Cyramza meets main goal in gastric cancer study

    Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a treatment for a type of gastric cancer met its main goal of preventing the disease from advancing. However the trial failed ...

  • Market Realist7 days ago

    How Is Eli Lilly’s Taltz Positioned Now?

    In 3Q17, Eli Lilly's (LLY) Taltz generated revenues of $151.3 million compared to $32.5 million in 3Q16.

  • Market Realist7 days ago

    How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

    In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.

  • Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
    Zacks7 days ago

    Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

    FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

  • Market Realist7 days ago

    How Eli Lilly’s Endocrinology Drugs Are Performing

    In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.

  • Eli Lilly raises dividend by 8%
    CNBC Videos4 days ago

    Eli Lilly raises dividend by 8%

    CNBC's Kate Rogers reports on Eli Lilly raising its dividend by 8% to 56.25 cents.